|
Cross-sectional associations at the 10-year follow-up between NT-proBNP (dependent variable) and rheumatoid arthritis disease activity, controlling for cardiovascular risk factors |
||||
| Adjusted linear regression |
Multivariate linear regression |
|||
|
|
||||
| β coefficients |
P value |
β coefficients |
P value |
|
|
|
||||
| Age |
1.04 (1.03–1.05) |
< 0.001 |
1.04 (1.03–1.05) |
< 0.001 |
| Male gender |
0.92 (0.64–1.31) |
0.64 |
0.76 (0.53–1.04) |
0.09 |
| Body mass indexa |
0.96 (0.93–0.98) |
0.001 |
||
| Atherogenic indexa |
0.95 (0.86–1.04) |
0.25 |
||
| Creatininea |
1.02 (1.01–1.02) |
0.001 |
1.01 (1.00–1.02) |
0.04 |
| C-reactive proteina |
1.01 (1.0–1.03) |
0.06 |
1.02 (1.00–1.02) |
0.03 |
| RF IgM-positivea, b |
0.92 (0.72–1.19) |
0.53 |
||
| Anti-CCP-positivea, b |
1.14 (0.88–1.45) |
0.33 |
||
| Ritchie scorea |
1.00 (0.99–1.01) |
0.87 |
||
| DAS28a |
1.05 (0.96–1.16) |
0.27 |
||
| HAQa |
1.15 (0.94–1.41) |
0.17 |
||
| Sharp scorea |
1.002 (1.00–1.01) |
0.17 |
||
| Disease durationa |
1.14 (1.02–1.27) |
0.02 |
1.15 (1.03–1.27) |
0.01 |
|
|
||||
| R2 adjusted |
0.38 |
< 0.001 |
||
|
aAge- and gender-adjusted; bdichotomized variable. anti-CCP, anti-cyclic citrullinated peptide antibody; DAS28, disease activity score of 28 joints; HAQ, Stanford Health Assessment Questionnaire; NT-proBNP, N-terminal pro-brain natriuretic peptide; RF, rheumatoid factor; Ritchie score, Ritchie articular index; Sharp score, van der Heijde modified Sharp criteria. | ||||
Provan et al. Arthritis Research & Therapy 2008 10:R70 doi:10.1186/ar2442 |
||||